Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients
- 1 September 2002
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (6) , 375-380
- https://doi.org/10.1038/sj.bmt.1703639
Abstract
Graft-versus-host disease (GVHD) is a major complication after hemopoietic stem cell transplantation (HSCT), but its pathogenesis remains uncertain. Macrophage migratory inhibitory factor (MIF) is an important mediator in the allo-immune reaction during renal transplantation, yet its role in hemopoietic stem cell transplantation (HSCT) remains unexplored. This study investigated the potential role of MIF in acute graft-versus-host disease (aGVHD) following allogeneic HSCT. Forty-six randomly selected patients undergoing autologous or allogeneic HSCT were studied. Immunohistochemistry and in situ hybridization were performed to examine tissue MIF mRNA and protein expression on skin and colonic biopsy specimens. The associated T cell and macrophage activation was also studied by immunohistochemical studies. A semi-quantitative method was used to assess MIF staining, as well as T cell and macrophage staining. Serial blood samples were analyzed by ELISA for serum MIF levels. Immunohistochemistry and in situ hybridization performed in 15 skin and 19 colonic biopsies from 17 patients who developed moderate to severe aGVHD showed a significant increase in MIF mRNA and protein expression compared with normal controls (seven skin and five colonic biopsies). MIF was localized within the epidermis and the vascular area of skin, but diffusely expressed in the entire thickness of colon. Macrophage and T lymphocyte infiltration was confined to areas of strong MIF expression. Serial analysis by ELISA showed that only patients who developed aGVHD (n = 19) exhibited an increase (two- to three-fold) in serum MIF during HSCT, but not in the allogeneic HSCT recipients without aGVHD (n = 7) or those who received autologous HSCT (n = 8). In 14 out of 19 patients, serum MIF peaked before the onset of aGVHD. Local and systemic up-regulation of MIF expression is associated with the occurrence of acute GVHD. Its pathogenetic role remains to be further determined.Keywords
This publication has 25 references indexed in Scilit:
- Expression of macrophage migration inhibitory factor in human glomerulonephritisKidney International, 2000
- Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid Counter-Regulator within the Immune SystemCritical Reviews in Immunology, 1997
- An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction.The Journal of Experimental Medicine, 1996
- MIF as a glucocorticoid-induced modulator of cytokine productionNature, 1995
- A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens.Journal of Histochemistry & Cytochemistry, 1995
- MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemiaNature, 1993
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974
- CHARACTERIZATION OF A LYMPHOCYTE FACTOR WHICH ALTERS MACROPHAGE FUNCTIONSThe Journal of Experimental Medicine, 1973
- ALTERATIONS OF MACROPHAGE FUNCTIONS BY MEDIATORS FROM LYMPHOCYTESThe Journal of Experimental Medicine, 1971
- Mechanism of a Reaction in Vitro Associated with Delayed-Type HypersensitivityScience, 1966